Why the study?
Do low-molecular-weight heparins offer improved safety and pharmacological profiles compared to conventional anticoagulants for thromboembolism prophylaxis?
Do low-molecular-weight heparins offer improved safety and pharmacological profiles compared to conventional anticoagulants for thromboembolism prophylaxis?
LMW heparins offer an improved pharmacological profile and safer applicability compared to conventional heparin, supporting their use for long-term thromboembolism prophylaxis.
Answers are grounded in this paper and cite their sources.
May support LMW heparins for long-term prophylaxis; leaves open prospective validation against modern agents.
In this overview, the rationale of the development of low-molecular-weight (LMW) heparins and their toxicological, anticoagulant, fibrinolytic, lipolytic, and protamine interactions are summarized. Clinical experiences are reviewed on the benefit of LMW heparin for anticoagulation in patients with bleeding and other complications on conventional anticoagulants and during pregnancy. It is concluded that animal experiments have demonstrated the safety of LMW heparins, that the pharmacologic profile is improved compared with normal heparin, and that the simple and safe applicability of LMW heparins gives rise to new indications for the long-term prophylaxis of thromboembolism.
No takes yet. Share an insight, caveat, or question.
Harenberg et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: